Sonpavde GP - Search Results

1

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.

Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Durán I, Lee JL, Matsubara N, Vulsteke C, Castellano D, Wu C, Campbell M, Matsangou M, Petrylak DP. Powles T, et al. Among authors: sonpavde gp. N Engl J Med. 2021 Mar 25;384(12):1125-1135. doi: 10.1056/NEJMoa2035807. Epub 2021 Feb 12. N Engl J Med. 2021. PMID: 33577729 Free PMC article. Clinical Trial.

2

Perioperative chemotherapy for bladder cancer.

Sonpavde G, Petrylak DP. Sonpavde G, et al. Crit Rev Oncol Hematol. 2006 Feb;57(2):133-44. doi: 10.1016/j.critrevonc.2005.05.004. Epub 2005 Jun 28. Crit Rev Oncol Hematol. 2006. PMID: 15990329 Review.

3

Novel agents for muscle-invasive and advanced urothelial cancer.

Sonpavde G, Ross R, Powles T, Sweeney CJ, Hahn N, Hutson TE, Galsky MD, Lerner SP, Sternberg CN. Sonpavde G, et al. BJU Int. 2008 Apr;101(8):937-43. doi: 10.1111/j.1464-410X.2007.07326.x. Epub 2007 Nov 13. BJU Int. 2008. PMID: 18005203 Review.

4

Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma.

Sonpavde G, Rosenberg JE, Hahn NM, Galsky MD, Bangs R, Sternberg CN, Vogelzang NJ. Sonpavde G, et al. J Clin Oncol. 2010 May 1;28(13):e205-7; author reply e208. doi: 10.1200/JCO.2009.27.1114. Epub 2010 Feb 16. J Clin Oncol. 2010. PMID: 20159797 No abstract available.

5

Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium.

Sonpavde G, Sternberg CN, Rosenberg JE, Hahn NM, Galsky MD, Vogelzang NJ. Sonpavde G, et al. Lancet Oncol. 2010 Sep;11(9):861-70. doi: 10.1016/S1470-2045(10)70086-3. Epub 2010 May 25. Lancet Oncol. 2010. PMID: 20537950 Review.

6

A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer.

Shamash J, Stebbing J, Sweeney C, Sonpavde G, Harland S, Dawkins G, Brock C, Abelman W, Wilson P, Sanitt A, Oliver T, Powles T. Shamash J, et al. Cancer. 2010 Aug 1;116(15):3595-602. doi: 10.1002/cncr.25194. Cancer. 2010. PMID: 20564115 Free article.

7

A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy.

Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg C, Bajorin DF, Bellmunt J. Galsky MD, et al. Lancet Oncol. 2011 Mar;12(3):211-4. doi: 10.1016/S1470-2045(10)70275-8. Lancet Oncol. 2011. PMID: 21376284 No abstract available.

8

Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.

Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg CN, Bajorin DF, Bellmunt J. Galsky MD, et al. J Clin Oncol. 2011 Jun 10;29(17):2432-8. doi: 10.1200/JCO.2011.34.8433. Epub 2011 May 9. J Clin Oncol. 2011. PMID: 21555688 Review.

9

Novel agents for advanced bladder cancer.

Sonpavde G, Elfiky AA, Rosenberg JE. Sonpavde G, et al. Ther Adv Med Oncol. 2009 Jul;1(1):37-50. doi: 10.1177/1758834009337776. Ther Adv Med Oncol. 2009. PMID: 21789112 Free PMC article.

10

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy.

de Bono JS, Molife LR, Sonpavde G, Maroto JP, Calvo E, Cartwright TH, Loesch DM, Feit K, Das A, Zang EA, Wanders J, Agoulnik S, Petrylak DP. de Bono JS, et al. Ann Oncol. 2012 May;23(5):1241-1249. doi: 10.1093/annonc/mdr380. Epub 2011 Sep 7. Ann Oncol. 2012. PMID: 21903605 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

481 results

Search Page